ELAN

English language groups host discussion on the future vitality of Quebec’s English-speaking community

Retrieved on: 
Tuesday, February 27, 2024

Montreal, Feb. 27, 2024 (GLOBE NEWSWIRE) -- The English Language Arts Network (ELAN) and the Provincial Employment Roundtable (PERT) are hosting a discussion on the topic of economic vitality for Quebec’s English-speaking community.

Key Points: 
  • Montreal, Feb. 27, 2024 (GLOBE NEWSWIRE) -- The English Language Arts Network (ELAN) and the Provincial Employment Roundtable (PERT) are hosting a discussion on the topic of economic vitality for Quebec’s English-speaking community.
  • In a moment characterized by decreased economic vitality for Québec’s English speakers, the discussion will be an opportunity to focus on the resilience of Quebec’s English-speaking community.
  • Nicholas Salter, Executive Director of PERT, emphasized the importance of addressing the challenges faced by English speakers in Quebec.
  • “We believe that it is important to facilitate a discussion that acknowledges the current challenges for English speakers in our province.

Ancora Nominates Four Highly Qualified, Independent Director Candidates and Urges Orderly CEO Succession at Elanco Animal Health

Retrieved on: 
Thursday, February 29, 2024

Based on extensive analysis and good faith engagement with Elanco, it appears that the biggest barriers to success are the Company’s insular Board and unaccountable CEO.

Key Points: 
  • Based on extensive analysis and good faith engagement with Elanco, it appears that the biggest barriers to success are the Company’s insular Board and unaccountable CEO.
  • Previously served on the Executive Leadership Team of Health for Animals, an organization that focuses on animal health products and animal well-being, and the Nutrition and Technology Innovation Advisory Board of Kiasco Animal Health, an animal health event series that connects innovation and investments.
  • Mr. Wallace is an experienced animal health and veterinary executive, most recently leading one of the largest animal health companies in the world.
  • Former Chief Executive Officer (North America/Pacific) of Ceva Santé Animale, the fifth largest animal health company worldwide.

Elanco Appoints Shiv O'Neill as General Counsel and Corporate Secretary

Retrieved on: 
Monday, March 4, 2024

GREENFIELD, Ind., March 4, 2024 /PRNewswire/ -- Elanco Animal Health (NYSE: ELAN) announced today the appointment of Shiv O'Neill as the company's Executive Vice President, General Counsel and Corporate Secretary.

Key Points: 
  • GREENFIELD, Ind., March 4, 2024 /PRNewswire/ -- Elanco Animal Health (NYSE: ELAN) announced today the appointment of Shiv O'Neill as the company's Executive Vice President, General Counsel and Corporate Secretary.
  • "Shiv's ability to deliver strategic value to Elanco in the short term serving as our interim general counsel combined with her robust experience made it clear that she was the right person for this role," said Jeff Simmons, President and CEO of Elanco.
  • Most recently, O'Neill served as Vice President, Deputy General Counsel, Americas of Elanco.
  • Prior to joining Elanco, O'Neill served as Senior Counsel at Cummins Inc. where she oversaw global litigation, product safety, crisis management, internal investigations and regulatory compliance matters.

Elanco Animal Health is Executing on Plan to Deliver for Shareholders

Retrieved on: 
Thursday, February 29, 2024

GREENFIELD, Ind., Feb. 29, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today issued the following statement in response to the submission of four nominees to the Company's Board of Directors by Ancora Holdings Group, LLC ("Ancora"):

Key Points: 
  • Elanco has returned to growth and is progressing a robust and innovative pipeline that will generate further growth.
  • Since revealing its candidates in writing two weeks ago, Ancora has refused to allow the Elanco Board to meet those candidates.
  • The leadership team is concentrated on minimizing any distractions and executing actions that we believe are in the best interest of all shareholders.
  • Spotlight Advisors is serving as financial advisor and Wachtell, Lipton, Rosen & Katz is serving as legal advisor to Elanco Animal Health.

Elanco to Participate in Upcoming Investor Conferences

Retrieved on: 
Thursday, February 22, 2024

GREENFIELD, Ind., Feb. 22, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that the Company will participate in the following investor conferences.

Key Points: 
  • GREENFIELD, Ind., Feb. 22, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that the Company will participate in the following investor conferences.
  • On Thursday, February 29, Todd Young, executive vice president and CFO, will participate in a fireside chat at the Bank of America 2024 Animal Health Summit at 2:10 p.m.
  • On Monday, March 4, Jeff Simmons, president and CEO, will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference at 10:30 a.m.
  • Live audio webcasts will be available in the "Events and Presentations" section of Elanco's investor website .

Beef 'agtech' company Cattler launches interface with Elanco for its Benchmark program

Retrieved on: 
Thursday, February 8, 2024

EKS Executive Director Michael Genho said, "we're excited to begin this data collaboration partnership with Cattler to better serve our joint customers.

Key Points: 
  • EKS Executive Director Michael Genho said, "we're excited to begin this data collaboration partnership with Cattler to better serve our joint customers.
  • Their innovative cattle management platform will give more global cattle producers access to Elanco's various data services and products.
  • Elanco's Benchmark converts data into information to help cattle feeders identify strengths and opportunities to pursue and measure performance over time.
  • Cattler Corporation is an 'agtech' startup company providing digital technology to the beef cattle industry.

Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2023 Financial Results Announcement

Retrieved on: 
Thursday, February 8, 2024

GREENFIELD, Ind., Feb. 8, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its fourth quarter and full year 2023 financial results on Monday, February 26, 2024.

Key Points: 
  • GREENFIELD, Ind., Feb. 8, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its fourth quarter and full year 2023 financial results on Monday, February 26, 2024.
  • Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance.
  • The conference call will begin at 8:00 a.m. eastern time.
  • Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website on our events and presentations page.

Merck Animal Health to Acquire Elanco’s Aqua Business

Retrieved on: 
Monday, February 5, 2024

Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that it has signed a definitive agreement to acquire the aqua business of Elanco Animal Health Incorporated (NYSE: ELAN) for $1.3 billion in cash, consisting of an innovative portfolio of medicines and vaccines, nutritionals and supplements for aquatic species; two related aqua manufacturing facilities in Canada and Vietnam; as well as a research facility in Chile.

Key Points: 
  • Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that it has signed a definitive agreement to acquire the aqua business of Elanco Animal Health Incorporated (NYSE: ELAN) for $1.3 billion in cash, consisting of an innovative portfolio of medicines and vaccines, nutritionals and supplements for aquatic species; two related aqua manufacturing facilities in Canada and Vietnam; as well as a research facility in Chile.
  • “We are excited for the acquisition of Elanco’s aqua products, solutions as well as the capabilities and expertise the team brings to our business,” said Rick DeLuca, president, Merck Animal Health.
  • The addition of this innovative portfolio of cold water and warm water aqua products across vaccines, anti-parasitic treatments, water supplements and nutrition, will establish Merck Animal Health as a leader in aqua.”
    Elanco Animal Health President and CEO Jeff Simmons said, “Following a robust process over the last year, Merck Animal Health emerged as the right strategic buyer for the aquaculture business.
  • In March 2019, Merck Animal Health acquired Scan Aqua AS, a fish health and fish welfare company based in Norway, focused on key aqua products.

Elanco Launches Multi-Year Mission to Save 1 Million Puppies from Canine Parvovirus

Retrieved on: 
Wednesday, January 17, 2024

GREENFIELD, Ind., Jan. 17, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today launched the first-of-its-kind, multi-year campaign to save 1 million puppies from unnecessary death from the highly contagious canine parvovirus (parvo). The Defend Puppies. Defeat Parvo. mission seeks to conquer a virus that, without timely and aggressive care, has a mortality rate as high as 91%1. An estimated 900 dogs are diagnosed with parvo daily2 in the U.S. – mostly unvaccinated puppies. Yet Elanco research revealed only 44% of dog owners know what parvo is, with 20% having no knowledge of the disease.3 With dog owners being the first line of defense in protecting their puppies, there is need for more wide-spread education.

Key Points: 
  • Pledge Today to Save Puppies from Deadly Canine Parvovirus
    GREENFIELD, Ind., Jan. 17, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today launched the first-of-its-kind, multi-year campaign to save 1 million puppies from unnecessary death from the highly contagious canine parvovirus (parvo).
  • mission strengthens Elanco's ability to reach more puppies, more quickly and includes the following:
    Newly established Elanco's Defenders Fund offers up to $1 million in rebate incentives from Elanco to veterinarians who purchase the Canine Parvovirus Monoclonal Antibody.
  • In clinical efficacy studies, zero dogs treated with Elanco's Canine Parvovirus Monoclonal Antibody died, and the Canine Parvovirus Monoclonal Antibody treatment helped shorten the course of parvo, helping these puppies feel better, faster.
  • I pledge, because I know together, we can save 1 million puppies from parvo by 2030.

2024 Feather in Her Cap and High Flyer Award Winners Named for Outstanding Achievements in Animal Health Industry

Retrieved on: 
Tuesday, January 16, 2024

The Feather in Her Cap Association, Inc. and 300 industry leaders honored 11 women for their outstanding career achievements in Animal Health at the seventh annual Feather in Her Cap awards ceremony.

Key Points: 
  • The Feather in Her Cap Association, Inc. and 300 industry leaders honored 11 women for their outstanding career achievements in Animal Health at the seventh annual Feather in Her Cap awards ceremony.
  • Andrea J. Gonzales Ph.D., vice president of Global Companion Animal Therapeutics at Zoetis, Inc., (NYSE: ZTS) was awarded the 2024 Feather in Her Cap award and Katharina Bohnenblust Ph.D., senior director, head of Formulation Development at Elanco Animal Health (NYSE: ELAN) was this year’s recipient of the 2024 High Flyer award.
  • Each year, the Feather in Her Cap award winner chooses an animal-related non-profit organization to receive a $5,000 donation.
  • The nomination process will reopen in Q3 of 2024 to celebrate more outstanding women in Animal Health in 2025.